- Oral presentation of updated data from Phase 3 Northstar-2 (HGB-207) study of LentiGlobin in patients with transfusion-dependent β-thalassemia (TDT) and non-β0/β0 genotypes –
- Oral presentation of interim data from patients treated with updated study protocol of Phase 1 HGB-206 study of LentiGlobin in patients with severe sickle cell disease (SCD) –
- Encore oral presentation of data from CRB-401 study of bb2121 in relapsed/refractory multiple myeloma–
- Company to host conference call and live webcast,
“As we progress towards our European regulatory filing for LentiGlobin
in TDT later this year, we look forward to sharing the updated data from
our Phase 3 HGB-207 study of LentiGlobin in people with TDT,” said
Oral Presentations
LentiGlobin
Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) in Patients
with Non-β0/β0
Genotypes: Updated Results from Northstar-2 (Abstract S833)
Presenter:
Date & Time:
Location:
Recent
Presenter:
Date & Time:
Location:
BB2121 Anti-BCMA CAR T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Phase I Study (Abstract S138)
Presenter:
Date & Time:
Location:
Note: This will be an encore of data presented at the
Poster Presentations
Early
MRD Negativity Predicts Deepening Myeloma Response in
Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with BB2121
Anti-BCMA CAR T Cells
Presenter:
Date & Time:
Location:
Poster Area
High Baseline Ferritin Is Associated with Grade 2 CRS Requiring Tocilizumab or Grade ≥ CRS in Relapsed/Refractory Multiple Myeloma Patients Treated with BB2121 Anti-BCMA CAR T Cells
Presenter:
Date & Time:
Location:
Poster Area
Conference Call & Webcast Information
bluebird bio will
host a conference call and live webcast at
About bluebird bio, Inc.
With its lentiviral-based gene
therapies, T cell immunotherapy expertise and gene editing capabilities,
bluebird bio has built an integrated product platform with broad
potential application to severe genetic diseases and cancer. bluebird
bio's gene therapy clinical programs include Lenti-D™ for the
treatment of cerebral adrenoleukodystrophy, and LentiGlobin™
for the treatment of transfusion-dependent β-thalassemia, also known as
β-thalassemia major, and severe sickle cell disease. bluebird bio's
oncology pipeline is built upon the company's leadership in lentiviral
gene delivery and T cell engineering, with a focus on developing novel T
cell-based immunotherapies, including chimeric antigen receptor (CAR T)
and T cell receptor (TCR) therapies. bluebird bio's lead oncology
programs, bb2121 and bb21217, are anti-BCMA CAR T programs partnered
with Celgene. bluebird bio also has discovery research programs
utilizing megaTAL/homing endonuclease gene editing technologies with the
potential for use across the company's pipeline.
bluebird bio has operations in Cambridge, Massachusetts, Seattle,
Washington, Durham, North Carolina and Zug,
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the Company's research, development, manufacturing
and regulatory approval plans for its LentiGlobin product candidate to
treat transfusion-dependent ß-thalassemia and severe sickle cell disease
and its bb2121 product candidate to treat relapsed/refractory multiple
myeloma. Any forward-looking statements are based on management's
current expectations of future events and are subject to a number of
risks and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include, but
are not limited to, the risks that the preliminary positive efficacy and
safety results from our prior and ongoing clinical trials of LentiGlobin
will not continue or be repeated in our ongoing, planned or expanded
clinical trials of LentiGlobin, the risks that the changes we have made
in the LentiGlobin manufacturing process or the HGB-206 clinical trial
protocol will not result in improved patient outcomes, risks that the
current or planned clinical trials of LentiGlobin will be insufficient
to support regulatory submissions or marketing approval in the US and
EU, the risk of a delay in the enrollment of patients in our clinical
studies, and the risk that any one or more of our product candidates,
including our bb2121 product candidate, will not be successfully
developed, approved or commercialized. For a discussion of other risks
and uncertainties, and other important factors, any of which could cause
our actual results to differ from those contained in the forward-looking
statements, see the section entitled "Risk Factors" in our most recent
Form 10-Q, as well as discussions of potential risks, uncertainties, and
other important factors in our subsequent filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20180517005646/en/
Source: bluebird bio, Inc.
bluebird bio, Inc.
Investors:
Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com
or
Media:
Stephanie
Fagan, 201-572-9581
sfagan@bluebirdbio.com